Premium
Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection
Author(s) -
Mehta Steinke Seema A.,
Alfares Mona,
Valsamakis Alexandra,
Shoham Shmuel,
AravBoger Ravit,
Lees Laura,
Ostrander Darin,
Forman Michael S.,
Shedeck Audra,
Ambinder Richard F.,
Jones Richard John,
Avery Robin K.
Publication year - 2021
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.13521
Subject(s) - cidofovir , medicine , foscarnet , serostatus , ganciclovir , refractory (planetary science) , cytomegalovirus , gastroenterology , nephrotoxicity , valganciclovir , immunology , human cytomegalovirus , viral load , virus , toxicity , viral disease , herpesviridae , physics , astrobiology
Background Treatment of ganciclovir‐resistant (GCV‐R)/refractory cytomegalovirus (CMV) infections in blood/marrow transplant (BMT) and solid organ transplant (SOT) recipients remains suboptimal. Cidofovir (CDV), a nucleotide analogue with anti‐CMV activity, is nephrotoxic and oculotoxic. Methods We retrospectively evaluated the outcomes of SOT and BMT patients with GCV‐R/refractory CMV treated with CDV between 1/1/2008 and 12/31/2017. Data collected: baseline demographics, CMV serostatus, clinical and virologic presentations and outcomes, UL97 and UL54 genotype mutations, drug toxicities, and cause of death. Descriptive statistics were used. Results 16 patients received CDV for treatment of CMV: six BMT and 10 SOT. Seven (47%) of the patients had high‐risk donor/recipient serostatus: six (60%) SOT were D+/R‐; one (16.7%) BMT was D−/R+. Median time to CMV DNAemia was 131 days post‐transplant (IQR, 37.5‐230.3). Proven tissue invasive disease was present in three patients (18.8%). Twelve (75%) had genotype testing; 10 (83.3%) of those had antiviral resistance mutations. While on CDV, six (37.5%) developed nephrotoxicity, and four (25%) developed uveitis (two had both uveitis and nephrotoxicity). Eight (50%) had failure to clear CMV DNAemia despite CDV treatment. Eight (50%) of the patients died; median time to death, after initiation of CDV, was 33.5 days [IQR22‐988]. Conclusions In the absence of good therapeutic alternatives, CDV is used in GCV‐R/refractory CMV infection. However, it is associated with a substantial risk of toxicity and failure to clear CMV DNAemia, highlighting the need for development of newer and less toxic therapies. The high mortality in this group of patients underscores the severity of illness in this population.